Articles by Gregg Brandyberry - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Gregg Brandyberry

Gregg Brandyberry


a partner of Wildfire Commerce, senior advisor of AT Kearney procurement and analytic solutions, and former vice-president of procurement, global systems, and operations for GlaxoSmithKline, 629 Overhill Road, Ardmore, PA 19003, tel. 215.327.5739

Articles
Creating a Holistic Procurement System
December 5, 2012

The procurement organization rethinks sourcing for maximum efficiency and results.

Creating a Holistic Procurement System
November 2, 2012

The procurement organization rethinks sourcing for maximum efficiency and results.

Reflecting on 35 Years of Procurement Transformation
July 2, 2012

The past three decades have driven a purchasing evolution to a procurement revolution.

Ways to Recover Lost Margins
May 2, 2012

Recovery audits and other past practices in procurement can improve the bottom line.

Ways to Recover Lost Margins
April 2, 2012

Recovery audits and other past practices in procurement can improve the bottom line.

Offsetting Budget Cuts
August 4, 2011

Better strategies and practices in sourcing and procurement can contribute to the bottom line.

Offsetting Budget Cuts
July 2, 2011

Better strategies and practices in sourcing and procurement can contribute to the bottom line.

A Hard Look at Third-Party External Supply Networks
May 4, 2011

The complexity of third-party external supply networks requires new ways to manage them.

A Hard Look at Third-Party External Supply Networks
April 2, 2011

The complexity of third-party external supply networks requires new ways to manage them.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FindPharma Custom Search
Click here